Valued at a market cap of $18.2 billion, Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the United States and internationally. Founded in 1967 and based in Secaucus, ...

The dynamic is prompting hospitals to take advantage of Quest Diagnostics’ expanding advanced diagnostics portfolio rather than building their in-house capabilities. The expansion of consumer ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Quest Diagnostics (DGX) launched a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer’s ...